DesaiTKKrishnanKSamalaN, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970-976.
2.
SikkemaMde JongePJSteyerbergEW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235-244.
3.
PhoaKNvan VilsterenFGWeustenBL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209-1217.
4.
MorrisZSWoodingSGrantJ. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510-520.
5.
WacholderSMcLaughlinJKSilvermanDT, et al. Selection of controls in case-control studies .1. Principles. Am J Epidemiol. 1992;135:1019-1028.
6.
HarrellFEJrLeeKLMarkDB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
7.
Ross-InnesCSChettouhHAchilleosA, et al. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2:23-31.
8.
VennalagantiPRKaulVWangKK, et al. Increased detection of Barrett’s esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. Gastrointest Endosc. 2018;87:348-355.
